



Boston Pharmaceuticals to Present at 2018 BIO CEO & Investor Conference

CAMBRIDGE, Mass. – February 6, 2018 - [Boston Pharmaceuticals](#) (the “Company”) today announced it will provide an overview of the company's programs and outlook at the 20th Annual BIO CEO & Investor Conference, being held February 12-13, 2018 in New York City. Presentation details:

Date: Tuesday, February 13, 2018

Time: 10:15 a.m. EST

Location: Gilbert Room, 4th Floor, New York Marriott Marquis

About Boston Pharmaceuticals

Boston Pharmaceuticals (the “Company”) is a clinical stage biopharmaceutical company developing differentiated therapeutics. By leveraging a highly experienced drug development team, Boston Pharmaceuticals is building a portfolio of high value clinical candidates addressing important unmet medical needs. The Company partners with innovative biotechnology companies, pharmaceutical companies and academic groups to acquire or in-license drug development candidates at late stages of pre-clinical development through early stages of clinical development. Following completion of human proof-of-concept trials, Boston Pharmaceuticals intends to partner successful development candidates to larger pharmaceutical or biotechnology companies for registration and commercialization, or alternatively build its own late stage portfolio, enabling the best molecules to reach patients while creating downstream value for the innovator and the Company. Boston Pharmaceuticals is funded by Gurnet Point Capital and is building a diversified portfolio of clinical candidates across multiple therapeutic areas. For more information, please visit www.bostonpharmaceuticals.com.

Boston Pharmaceuticals Contact

Kari Watson, MacDougall Biomedical Communications

kwatson@macbiocom.com

781-235-3060